Advanced in Dementia

Roger M. Clarnette

35 Stirling Hwy, 
Crawley, WA, AU 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Dementia
35 Stirling Hwy, 
Crawley, WA, AU 
OverviewLocationsClinical Research

Overview

Roger Clarnette practices in Crawley, Australia. Mr. Clarnette is rated as an Advanced expert by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, and Developmental Dysphasia Familial.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles and participated in 6 clinical trials in the study of Dementia.

Gender
Male

Locations

35 Stirling Hwy, Crawley, WA 6009, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: XPro1595
Study Phase: Phase 1
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Translational Study of ATH-1017 in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
View 5 Less Clinical Trials

27 Total Publications

Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.
Journal: Acta neuropathologica
Published: February 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Clarnette's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile